Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ensysce Biosciences (ENSC) Operating Income (2020 - 2025)

Historic Operating Income for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to -$3.7 million.

  • Ensysce Biosciences' Operating Income fell 68024.32% to -$3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.0 million, marking a year-over-year decrease of 7490.88%. This contributed to the annual value of -$6.7 million for FY2024, which is 3720.83% up from last year.
  • Per Ensysce Biosciences' latest filing, its Operating Income stood at -$3.7 million for Q3 2025, which was down 68024.32% from -$1.8 million recorded in Q2 2025.
  • In the past 5 years, Ensysce Biosciences' Operating Income ranged from a high of $644746.0 in Q3 2024 and a low of -$16.9 million during Q3 2021
  • In the last 5 years, Ensysce Biosciences' Operating Income had a median value of -$2.6 million in 2023 and averaged -$3.6 million.
  • Its Operating Income has fluctuated over the past 5 years, first crashed by 407190.7% in 2021, then surged by 12381.5% in 2024.
  • Ensysce Biosciences' Operating Income (Quarter) stood at -$2.0 million in 2021, then crashed by 209.0% to -$6.2 million in 2022, then surged by 49.11% to -$3.2 million in 2023, then decreased by 13.33% to -$3.6 million in 2024, then decreased by 4.6% to -$3.7 million in 2025.
  • Its Operating Income was -$3.7 million in Q3 2025, compared to -$1.8 million in Q2 2025 and -$2.0 million in Q1 2025.